Drug intelligence / Profile preview

EP0089

Development stage: Phase 2
Lead developer: Ellipses Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

EP0089 is a first-in-class next-generation immunotherapy monoclonal antibody targeting CNTN4 (Contactin-4), a recently discovered immune checkpoint protein highly expressed in a wide range of solid tumors. By blocking the interaction between CNTN4 and APP on T cells, EP0089 aims to promote tumor cell killing and overcome resistance seen with conventional checkpoint inhibitors. The drug was originally discovered by Genome & Company and is being developed globally by Ellipses Pharma. It represents a novel approach in immuno-oncology for patients with cancers that respond poorly to existing therapies[4][5].

Other names: anti-CNTN4 antibody GENA-104A16anti-CNTN-4 antibody GENA-104A16anti-CNTN 4 antibody GENA-104A16

Targets

CNTN4 (Contactin-4)

Beyond the preview

Go deeper on EP0089.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP0089.

Explore the full profile